Abstract
The history of monoamine oxidase inhibitor (MAOI) use in psychiatry is a curious one and far from complete. The inspiration for our own use derived from the work of Chessin et al. (1956) who found that “marsalinizing” (treating with Marsilid, i.e., iproniazid) an animal before administering reserpine produced a paradoxical effect1. The animal rather than becoming sedated became hyperalert and active. Scott described these findings during a visit to Warner Laboratories as part of a discussion which dealt with the mode of action of reserpine. The possibility of using this combination to activate retarded schizophrenic patients and to treat depression suggested itself.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ananth, J., Luchins, D.: A review of combined tricyclic and MAOI therapy. Compr. Psychiatry 18, 221–230 (1977)
Asatoor, A.M., Levi, A.J., Milne, M.D.: Tranylcypromine and cheese. Lancet 2, 733–734 (1963)
Axelrod, J.: O-methylation of epinephrine and other catechols in vitro and in vivo. Science 126, 400 (1957)
Ayd, F.J.: A preliminary report on marsilid. Am. J. Psychiatry 114, 459 (1957)
Bailey, S.D., Bucci, L., Gosline, E., Kline, N.S., Park, I.H., Rochlin, D., Saunders, J.C., Vaisberg, M.: Comparison of iproniazid with other amine oxidase inhibitors, including W-1544, JB-516, R04-1018, and R05-0700. Ann. N.Y. Acad. Sci. 80, 652–668 (1959)
Baldessarini, R.J.: Mood drugs. In: Disease-A-Month. Dowling, H.F. (ed.), Vol. 24, 2., Chicago: Year Book Medical Publishers 1977
Berger, P.A., Barchas, J.D.: Monoamine oxidase inhibitors. In: Psychotherapeutic drugs. Usdin, E., Forrest, I. (eds.). New York: Dekker 1977
Biel, J.H., Bopp, B.: Monoamine oxidase inhibitor antidepressants. In: Psychopharmacological agents. Gordon, M. (ed.), pp. 302–309. New York: Academic Press 1974
Birkmayer, W., Yahr, M. (eds.): Deprenyl, an inhibitor of MAO-type B in the treatment of Parkinsonism. J. Neural. Transm. 43, 3–4 (1978)
Blackwell, B., Marley, E., Ryle, A.: Hypertensive crisis associated with monoamine-oxidase inhibitors. Lancet 1, 722–723 (1964)
Brodie, B.B., Pletscher, A., Shore, P.A.: Possible role of serotonin in brain function and in reserpine action. J. Pharmacol. Exp. Ther. 116, 9 (1956)
Bunney, W.E., Davis, J.M.: Norepinephrine in depressive reactions. A review. Arch. Gen. Psychiatry 13, 483–494 (1965)
Burn, J.H., Philpot, F.J., Trendelenburg, U.: Effect of denervation on enzymes in iris and blood vessels. Br. J. Pharmacol. 9, 423–428 (1954)
Chessin, M., Dubnick, B., Kramer, E.R., Scott, C.C.: Modifications of pharmacology of reser-pine and serotonin by iproniazid. Fed. Proc. 15, 409 (1956)
Cooper, A.J., Ashcroft, G.: Potentiation of insulin hypoglycaemia by MAOI antidepressant drugs. Lancet 1, 407–409 (1966)
Crane, G.E.: Further studies on iproniazid phosphate. Isonicotinil-isopropylhydrazine phosphate Marsilid. J. Nerv. Ment. Dis. 124, 322–331 (1956)
Crane, G.E.: The psychiatric side-effects of iproniazid. Am. J. Psychiatry 112, 494–501 (1956)
Davidson, J., McCleod, M.N., Blum, M.R.: Acetylation phenotype, platelet monoamine oxidase inhibition, and the effectiveness of phenelzine in depression. Am. J. Psychiatry 135, 467–469 (1978)
Dunleavy, D.L.F., Oswald, I.: Phenelzine, mood response and sleep. Arch. Gen. Psychiatry 28, 353–356 (1973)
Escobar, J.I., Schiele, B.C., Zimmermann, R.: The tranylcypromine isomers: A controlled clinical trial. Am. J. Psychiatry 131, 1025–1026 (1974)
Evans, D.A.P., Manley, K.A., McKusick, V.A.: Genetic control of isoniazid metabolism in man. Br. Med. J. 2, 485–491 (1960)
Evans, D.A.P., Davison, K., Pratt, R.T.C.: The influence of acetylator phenotype on the effects of treating depression with phenelzine. Clin. Pharmacol. Ther. 6, 430–435 (1965)
Fisher, M.M., Mammlok, E.R., Tendlau, A., Tebrock, H.E., Drumm, A.E., Spiegelman, A.: Isonicotinic acid hydrazide and its derivatives in tuberculosis: An evaluation of the side-effects in relation to peripheral circulation; preliminary report. 52, 1519–1527 (1952)
Fowler, C.J., Callingham, B.A., Mantle, T.J., Tipton, K.F.: Monoamine oxidase A and B: A useful concept? Biochem. Pharmacol. 27, 97–101 (1978)
Franzen, F., Eysell, K. (eds.): Biologically active amines found in man. Oxford: Pergamon Press 1969
Friend, D.G., Zileli, M.S., Hamlin, J.T., Reutter, F.W.: The effect of iproniazid on the inacti-vation of norepinephrine in the human. J. Clin. Exp. Psychopathol. 19, 61–71 (1958)
Fuller, R.W.: Selective inhibition of monoamine oxidate. Adv. Biochem. Psychopharm. 5, 339–354 (1972)
Fuller, R.W.: Selectivity among monoamine oxidase inhibitors and its possible importance for development of antidepressant drugs. Prog. Neuropsychopharmacol. 2, 303–311 (1978)
Fuller, R.W., Roush, B.W.: Procaine hydrochloride as a monoamine oxidase inhibitor: Implications for geriatric therapy. J. Am. Geriatr. Soc. 25, 90–93 (1977)
Gaddum, J.H., Kwiatkowski, H.: The action of ephedrine. J. Physiol. (Lond.) 94, 87–100 (1938)
Goodman, L.S., Gilman, A.: The pharmacological basis of therapeutics. 2nd ed., p. 517. New York: Macmillan 1965
Hendley, E.D., Snyder, S.H.: Relationship between the action of monoamine oxidase inhibitors on the noradrenaline uptake system and their antidepressant efficacy. Nature 220, 1330–1331 (1968)
Hodge, J.V., Nye, E.R., Emerson, G.W.: Monoamine-oxidase inhibitors, broad beans, and hypertension. Lancet 1, 1108 (1964)
Horwitz, D., Goldberg, L.I., Sjoerdsma, A.: Increased blood pressure responses to dopamine and norepinephrine produced by monoamine oxidase inhibitors in man. J. Lab. Clin. Med. 56, 747–753 (1960)
Horwitz, D., Lovenberg, W., Engelman, K., Sjoerdsma, A.: Monoamine oxidase inhibitors, tyramine, and cheese. J. Am. Med. Assoc. 188, 1108 (1964)
Houslay, M.D., Garrett, N.J., Tipton, K.F.: Mixed substrate experiments with human brain monoamine oxidase. Biochem. Pharmacol. 23, 1937–1944 (1974)
Houslay, M.D., Tipton, K.F., Youdim, M.B.H.: Minireview Multiple forms of monoamine oxidase: Fact and artefact. Life Sci. 19, 467–478 (1976)
Jarvik, M.: Drugs used in the treatment of psychiatric disorders. In: The pharmacological basis of therapeutics. 5 th ed. Goodman, L.S., Gilman, A. (eds.), pp. 151–203. New York: MacMillan 1970
Johnston, J.P.: Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol. 17, 1285–1297 (1968)
Johnstone, E.C., Marsh, W.: Acetylator status and response to phenelzine in depressed patients. Lancet 1, 567–570 (1973)
Kamman, G.R., Freeman, J.G., Lucero, R.J.: The effect of l-isonicotynil-2-isopropyl hydrazine (IIH) on the behavior of long-term mental patients. J. Nerv. Ment. Dis. 118, 391–407 (1953)
Kiloh, L.G., Child, J.P., Latner, G.: A controlled trial of iproniazid in the treatment of endogenous depression. J. Ment. Sci. 106, 1139–1144 (1960)
Kline, N.S.: Present status of psychopharmacological Research: Includes Loomer, H., Saunders, J.C., Kline, N.S.: Iproniazid, an amine oxidase inhibitor, as an example of a psychic energizer. Hearings before the subcommittee of the Committee on Appropriations, United States Senate, 85th Congress, 1st Session on H.R. 6287, pp. 1372–1390, May 9, 1957. Washington, D.C.: U.S. Government Printing Office 1957
Kline, N.S.: Quoted in: Berger, P.A., Barchas, J.D. In: Psychotherapeutic drugs. Usdin, E., Forrest, I. (eds.), p. 1175. New York: Dekker 1977
Kline, N.S., Sacks, W.: Relief of depression within one day using an M.A.O. inhibitor and intravenous 5-HTP. Am. J. Psychiatry 120, 274–275 (1963)
Kline, N.S., Sacks, W.: Treatment of depression with an MAO inhibitor followed by 5-HTP — an unfinished research project. Presented at Symposium on Biogenic Amines and Affective Disorders. London. Jan. 18–21, 1979
Kline, N.S., Alexander, S.F., Chamberlain, A.: In: Psychotropic drugs. Manual for emergency management overdosage. New Jersey: Medical Economics Company 1974
Kline, N.S., Sacks, W., Simpson, G.M.: Further studies on: One day treatment of depression with 5-HTP. Am. J. Psychiatry 121, 379–381 (1964)
Kopin, I.J., Axelrod, J.: The role of monoamine oxidase in the release and metabolism of norepinephrine. Ann. N.Y. Acad. Sci. 107, 848 (1963)
Krikler, D.M., Lewis, B.: Dangers of natural foodstuffs. Lancet 1, 1166 (1965)
Lader, M.: Antianxiety drugs: Clinical pharmacology and therapeutic use. Drugs 12, 362–373 (1976)
Leonard, B.E.: Some effects of mianserin on monoamine metabolism in the rat brain. Br. J. Clin. Pharmacol. 5, 11S–12S (1978)
Loomer, H.P., Saunders, J.C., Kline, N.S.: A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiatr. Res. Rep. 8, 129–141 (1958)
Maclean, R., Nicholson, W.J., Pare, C.M.B., Stacey, R.S.: Effect of monoamine-oxidase inhibitors on the concentrations of 5-hydroxytryptamine in the human brain. Lancet 2, 205–208 (1965)
Marley, E.: Monoamine oxidase inhibitors. In: Drug interactions. Grahame-Smith, D.G. (ed.), pp. 178–194. Baltimore: University Park Press 1977
Marshall, E.F., Mountjoy, C.O., Campbell, I.C., Garside, R.F., Leitch, I.M., Roth, M.: The influence of acetylator phenotype on the outcome of treatment with phenelzine, in a clinical trial. Br. J. Clin. Pharmacol. 6, 247–254 (1978)
Mielke, D.H.: Adverse reactions of thymoleptics. In: Depression: Behavioral, biochemical, diagnostic and treatment concepts. Gallant, D.M., Simpson, G.M. (eds.), pp. 273–308. Stuttgart: Spectrum Publications 1976
Morris, J.B., Beck, A.T.: The efficacy of antidepressant drugs. A review of research (1958 to 1972). Arch. Gen. Psychiatry 30, 667–674 (1974)
Murphy, D.L.: The behavioral toxicity of monoamine oxidase-inhibiting antidepressants. Adv. Pharmacol. Chemother. 14, 71–105 (1977)
Murphy, D.L., Donnelly, C.H.: Monoamine oxidase in man: enzyme characteristics in platelets, and other human tissue. In: Neuropsychopharmacology of monoamines and their regulatory enzymes. Usdin, E. (ed.), pp. 71–85. New York: Raven Press 1974
Murphy, D.L., Belmaker, R., Wyatt, R.J.: Monoamine oxidase in schizophrenia and other behavioral disorders. J. Psychiatr. Res. 11, 221–247 (1974)
Neff, N.H., Yang, H.-Y.T.: Life Sci. 14, 2061–2074 (1974)
Nelson, S.D., Mitchell, J.R., Timbrell, J.A., et al: Isoniazid and iproniazid: Activation of metabolites to toxic intermediates in man and rat. Science 193, 901–903 (1976)
Nies, A., Robinson, D.S., Lamborn, K.R., Lampert, R.P.: Genetic control of platelet and plasma monoamine oxidase activity. Arch. Gen. Psychiatry 28, 834–838 (1973)
Nies, A., Robinson, D.S., Harris, L.S., Lamborn, K.R.: Comparison of monoamine oxidase substrate activity in twins, schizophrenics, depressives, and controls. In: Advances in bio-chem. psychopharmacol. Neuropsychopharmacology of monoamine and their regulatory enzymes. Usdin, E. (ed.). New York: Raven Press 1974
Ostow, M., Kline, N.S.: The psychic action of reserpine and chlorpromazine. In: Psychophar-macology frontiers. Kline, N.S. (ed.), Appendix, pp. 481–513. Boston, Mass.: Little, Brown & Co. 1959
Paykel, E.S.: Classification of depressed patients: A cluster analysis derived grouping. Br. J. Psychiatry 118, 275–288 (1971)
Pletscher, A., Shore, P.A., Brodie, B.B.: Serotonin as a mediator of reserpine action in brain. J. Pharmacol. Exp. Ther. 116, 84–89 (1956)
Raskin, A.: Adverse reactions to phenelzine: Results of a nine-hospital depression study. J. Clin. Pharmacol. 12, 22–25 (1972)
Robinson, D.S., Lovenberg, W., Keiser, H., Sjoerdsma, A.: Effects of drugs on human blood platelet and plasma amine oxidase activity in vitro and in vivo. Biochem. Pharmacol. 17, 109–119(1968)
Robinson, D.S., Nies, A., Ravaris, C.L., Ives, J.O., Bartlett, D.: Clinical psychopharmacology of phenelzine: MAO activity and clinical response. In: Psychopharmacology: A generation of progress. Lipton, M.A., DiMascio, A., Killam, K.F. (eds.). New York: Raven Press 1978
Rosloff, B.N., Davis, J.M.: Effect of iprindole on norepinephrine turnover and transport. Psychopharmacologia (Berl.) 40, 53–64 (1974)
Saunders, J.C., Radinger, N., Rochlin, D., Kline, N.S.: Treatment of depressed and regressed patients with iproniazid and reserpine. Dis. Nerv. Syst. 20, 1–8 (1959)
Schiele, B.C.: The parnate specific patient. Minn. Med. 48, 355–357 (1965)
Schildkraut, J.J.: The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am. J. Psychiatry 122, 509–522 (1965)
Schuckit, M., Robins, E., Feighner, J.: Tricyclic antidepressants and monoamine oxidase inhibitors: Combination therapy in the treatment of depression. Arch. Gen. Psychiatry 24, 509–514 (1971)
Selikoff, I.J., Robitzvek, E.H., Ornstein, G.G.: Toxicity of hydrazine derivatives of isonicotinic acid in the chemotherapy of human tuberculosis. Q. Bull. Sea View Hosp. 13, 17–26 (1952)
Shaw, D.M.: The practical management of affective disorders. Br. J. Psychiatry 130, 432–451 (1977)
Shopsin, B., Kline, N.S.: Monoamine oxidase inhibitors: Potential for drug abuse. Biol. Psychiatry 11, 451–456 (1976)
Sjoqvist, F.: SPIIn: Monoamine oxidase inhibitors: Relationship between pharmacological and clinical effects. Cheymol, J., Boissier, J.R., Vol. 10. New York: Pergamon Press 1968
Smith, J.A.: The use of the isopropyl derivative of isonicotinylhydrazine (marsilid) in the treatment of mental disease; A preliminary report. Am. Practitioner 4, 519–520 (1953)
Spector, S., Hirsch, C.W., Brodie, B.B.: Association of behavioral effects of pargyline, a non-hydrazide monoamine oxidase inhibitor with increase in brain norepinephrine. Int. J. Neuropharmacol. 2, 81–93 (1963)
Spiker, D.G., Pugh, D.D.: Combining tricyclic and monoamine oxidase inhibitor antidepressants. Arch. Gen. Psychiatry 33, 828–830 (1976)
Tyrer, P., Candy, J., Kelly, D.: Phenelzine in phobia anxiety: A controlled trial. Psychol. Med. 3, 120–124 (1973)
Usdin, E. (ed.): Neuropsychopharmacology of monoamines and their regulatory enzymes. Advances in biochemical psychopharmacology, Vol. 12. New York: Raven Press 1974
Von Bruecke, F., Hornykiewicz, O., Sigg, E.B.: Monoamine oxidase inhibitors. In: The pharmacology of psychotherapeutic drugs. pp. 78–102. Berlin, Heidelberg, New York: Springer 1969
West, E.D., Dally, P.J.: Effects of iproniazid in depressive syndromes. Br. Med. J. 1, 1491–1494 (1959)
Yang, H.-Y.T., Neff, N.H.: B-phenylethylamine: A specific substrate for type B monoamine oxidase of brain. J. Pharmacol. Exp. Ther. 187, 365–371 (1973)
Youdim, M.B.: Multiple forms of mitochondrial monoamine oxidase. Br. Med. Bull. 29, 120–122 (1973)
Zeller, E.A., Barsky, J.: In vivo inhibition of liver and brain monoamine oxidase by 1-isonicotinyl-2-isopropyl hydrazine. Proc. Soc. Exp. Biol. Med. 81, 459–461 (1952)
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Kline, N.S., Cooper, T.B. (1980). Monoamine Oxidase Inhibitors as Antidepressants. In: Hoffmeister, F., Stille, G. (eds) Psychotropic Agents. Handbook of Experimental Pharmacology, vol 55 / 1. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-67538-6_17
Download citation
DOI: https://doi.org/10.1007/978-3-642-67538-6_17
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-67540-9
Online ISBN: 978-3-642-67538-6
eBook Packages: Springer Book Archive